The Role of PARPi in Prostate Cancer:
On August 26th and August 28th 2020, two “Experts Knowledge Share” interactive webinars connected global participants with renowned panel experts to discuss the therapeutic role of PARP inhibitors in prostate cancer. Panellists included Dr. Neal D. Shore (Programme Chair; Carolina Urologic Research Center), Prof. Andrew J. Armstrong (Duke University School of Medicine), and Prof. Emmanuel S. Antonarakis (Johns Hopkins Medicine).
Key topics included:
- Prevalence of DDR mutations in prostate cancer, and somatic and germline testing
- PARPi mechanism of action
- Recent clinical trial data and ongoing studies
- Efficacy and safety profiles of PARPi
- Patient case studies